deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT01356628

A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer

A Phase II Study of PD-0332991 in Adult Patients With Advanced Hepatocellular Carcinoma

Sponsor: Pfizer

Conditions Advanced Hepatocellular Carcinoma HCC Liver Cancer
Interventions PD-0332991
Updated 19 times since 2017 Last updated: Jul 16, 2025 Started: May 25, 2011 Primary completion: Jun 1, 2023 Completion: Dec 16, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Advanced Hepatocellular Carcinoma and HCC, this trial is completed. The trial is conducted by Pfizer and has accumulated 19 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Nov 2017 · 9 months · monthly snapshot~Nov 2017 – ~Jan 2018 · 2 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~Dec 2019 · 10 months · monthly snapshot~Dec 2019 – ~Jul 2020 · 7 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Dec 2022 · 13 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jan 2024 · 12 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Aug 2025 · 9 months · monthly snapshot~Aug 2025 – ~Feb 2026 · 6 months · monthly snapshot~Feb 2026 – present · 7 months · monthly snapshot

Change History

19 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE2

  2. Aug 2025 — Feb 2026 [monthly]

    Completed PHASE2

  3. Nov 2024 — Aug 2025 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 14 earlier versions

  1. Jan 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Dec 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Nov 2021 — Dec 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Jul 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  8. Dec 2019 — Jul 2020 [monthly]

    Active Not Recruiting PHASE2

  9. Feb 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2

  10. Jun 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE2

  11. Jan 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  12. Nov 2017 — Jan 2018 [monthly]

    Active Not Recruiting PHASE2

  13. Feb 2017 — Nov 2017 [monthly]

    Active Not Recruiting PHASE2

  14. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Data source: Thomas Jefferson University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations